Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05538247 · ClinicalTrials.gov registry record · Early Phase 1
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
A Early Phase 1 study of Healthy, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT05538247: Recruiting Early Phase 1 study of Healthy, sponsored by Mayo Clinic.
NCT05538247 is a Early Phase 1 study of Healthy that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 56 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05538247, a Early Phase 1 study of Healthy, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
Primary Outcome
Change in intestinal permeability parameters urinary lactulose and 13C (13carbon) mannitol in 0-2 hrs, 2-8 hrs, 8-24 hr urine collection
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Indomethacin
- DIETARY_SUPPLEMENT S. boulardii CNCM I-745
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2023-04-13 |
| Est. Completion | 2026-03-31 |
| Phase | Early Phase 1 |
What NCT05538247 shows while recruiting
NCT05538247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT05538247 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT05538247 about?
NCT05538247 is a clinical study titled "Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function". This study is being done to assess the effects of S. boulardii CNCM I-745 compared to placebo on impaired intestinal permeability, which is the control of material passing from inside the gastrointestinal tract through the cells lining the gut wall into the rest of the body.
What is the current status of trial NCT05538247?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 56 participants. The study started on 2023-04-13. Estimated completion is 2026-03-31.
What conditions does trial NCT05538247 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT05538247?
The interventions under investigation include: Placebo (DRUG), Indomethacin (DRUG), S. boulardii CNCM I-745 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05538247?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05538247 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05538247's enrollment target sits among peer trials
56 413th of 1090 higher than 665 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
-
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI